NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Greater Glasgow and Clyde Medicines
For all prescribers and health professionals both in primary care and the acute sector.
All editions of PostScript (the previous name for Medicines Update) from 2011 onwards have been added to this site. Click here for an index to all previous editions. If you would like a copy of a previous edition, please contact medicines.update@ggc.scot.nhs.uk
Posted: July 25, 2017.
Category - Medicines Update
Following agreement between NHS Education Scotland (NES), cardiology and pharmacy services in NHSGGC (September 2013), patients
Posted: July 25, 2017.
Category - Medicines Update
Tagged with - Biologics
Following SMC advice that ticagrelor 60mg twice daily is not recommended for use in NHS Scotland, NHSGGC Heart MCN has recommended that the small number of patients currently receiving this should have their prescription changed to clopidogrel ...
Posted: July 10, 2017.
Category - Medicines Update
Tagged with - MHRA Drug Safety Update
Drug Safety Update (June 2017) includes: Denosumab (Prolia, Xgeva ▼): reports of osteone...
Posted: July 03, 2017.
Category - Medicines Update
Tagged with - Formulary
Two new lipid lowering medicines, alirocumab and evolocumab (PCSK9 inhibitors) are on the GGC Formulary for initiation by specialist lipid clinics. Use is restrict...
Posted: June 23, 2017.
Category - Medicines Update
Tagged with - Diabetes
The position of alogliptin in the NHSGGC Formulary has changed. The previous prescribing restriction limiting use in dual therapy has been remov...
Posted: June 23, 2017.
Category - Medicines Update
Tagged with - Diabetes
Fast acting Insulin aspart (Fiasp®) has been accepted by the SMC and added to the Formulary. It is a modified formulation of insulin aspart with the property of more rapid absorption of insulin from subcutaneous injection site than standard...
Posted: June 23, 2017.
Category - Medicines Update
Tagged with - Respiratory
In April 2017, the ADTC accepted the Respiratory MCN’s recommendation on tiotropium inhaler devices. Braltus® Zonda Inhaler is now the preferred brand of tiotropium inhaler. Spiriva Respimat® remains a Total Formulary option. ...
Posted: June 23, 2017.
Category - Medicines Update
Tagged with - Opioids
Butec® is the NHSGGC preferred brand of buprenorphine 7 day transdermal patch across primary and secondary care. It is restricted to specialist use only in elderly patients (over 65 years) where standard analgesic options are ineffective or...
Posted: May 26, 2017.
Category - Medicines Update
This blog summarises the main changes of the cholesterol guidelines updated in 2017
Posted: May 19, 2017.
Category - Medicines Update
Tagged with - Osteoporosis
NHSGGC Osteoporosis Strategy Group has produced a clinical guideline on the